Hohage H, Arlt M, Brückner D, Dietl K H, Zidek W, Spieker C
Clinic for Medicine, Wilhelms Westfalian University, Münster, Germany.
Clin Transplant. 1997 Jun;11(3):225-30.
After allogenic transplantations a dramatic increase in the development of arteriosclerotic plaques can be observed, which might be due to metabolic alterations, influenced by changes of the transplant organ or immunosuppression. In this study the effects of FK 506 in kidney transplant patients on cardiovascular risk factors were compared to cyclosporin A (CsA) immunosuppression. Both groups showed no statistical differences in number, kidney function, age, body weight, sex distribution, steroid dosage and follow-up time after transplantation. Total cholesterol was similar in FK 506-treated patients (231 +/- 22 vs. 278 +/- 52 mg/dl) as compared with patients with CsA immunosuppression. Furthermore, there were no differences in triglycerides (220 +/- 72 vs. 210 +/- 67 mg/dl), HDL-cholesterol (67 +/- 14 vs. 52 +/- 18 mg/dl) and fasting glucose (112 +/- 36 vs. 116 +/- 17 mg/dl). However, the concentration of LDL-cholesterol (114 +/- 21 vs. 167 +/- 37 mg/dl), the independent risk factor Lp(a) (11 +/- 9 vs. 27 +/- 8 mg/dl) and fibrinogen (216 +/- 71 vs. 297 +/- 47) was lower in FK 506-treated patients. Our results indicate that FK 506 immunosuppression offers some advantages in cardiovascular risk factors.
在同种异体移植后，可以观察到动脉粥样硬化斑块的发展显著增加，这可能是由于代谢改变，受移植器官变化或免疫抑制的影响。在本研究中，将肾移植患者中FK 506对心血管危险因素的影响与环孢素A（CsA）免疫抑制进行了比较。两组在移植后的数量、肾功能、年龄、体重、性别分布、类固醇剂量和随访时间方面均无统计学差异。与接受CsA免疫抑制的患者相比，FK 506治疗患者的总胆固醇相似（231±22对278±52mg/dl）。此外，甘油三酯（220±72对210±67mg/dl）、高密度脂蛋白胆固醇（67±14对52±18mg/dl）和空腹血糖（112±36对116±17mg/dl）也没有差异。然而，FK 506治疗患者的低密度脂蛋白胆固醇浓度（114±21对167±37mg/dl）、独立危险因素Lp(a)（11±9对27±8mg/dl）和纤维蛋白原（216±71对297±47）较低。我们的结果表明，FK 506免疫抑制在心血管危险因素方面具有一些优势。
Zotero 插件